Union Minister of Commerce and Industry Shri Piyush Goyal said that India’s pharmaceutical sector showcases the nation’s commitment to affordable, quality healthcare worldwide.
Key Developments
- India aims to reach USD 50 billion in pharmaceutical exports by 2030, focusing on quality, innovation and market diversification.
- The upcoming iPHEX 2026 will be held at Bharat Mandapam, New Delhi, from 7–9 September 2026.
- The Global Drug Regulatory Conclave 2026 is scheduled for 30–31 July 2026, aiming at regulatory cooperation.
- Minister of State Shri Jitin Prasada called for stronger global collaboration to build resilient health systems.
- Commerce Secretary Shri Rajesh Agrawal highlighted that over 60 % of pharma exports go to highly regulated markets.
Important Facts
Pharmaceutical exports have risen from about USD 14 billion (FY 2014‑15) to USD 31 billion (FY 2025‑26), reaching patients in more than 200 countries. India houses over 10,500 manufacturing units and produces more than 60,000 generic brands across 60 therapeutic categories.
During the COVID‑19 pandemic, India not only met domestic demand but also supplied medicines and vaccines to numerous nations, especially in the Global South.
UPSC Relevance
The discussion ties into several UPSC themes:
- Vasudhaiva Kutumbakam and the One Earth, One Health philosophy shape India’s health diplomacy.
- Generic medicines illustrate India’s comparative advantage and its role in global drug access.
- Pharmaceutical exports contribute significantly to the trade surplus and employment generation.
- The push for regulatory convergence aligns with the need for international cooperation in trade and health security, a recurring topic in GS 3.
Way Forward
To achieve the $50 bn target, the Ministry plans to:
- Strengthen quality and compliance to meet the standards of highly regulated markets.
- Encourage R&D and innovation for higher‑value products, moving beyond generics.
- Facilitate foreign investment and contract manufacturing through policy incentives.
- Deepen regulatory cooperation via platforms like the Global Drug Regulatory Conclave.
- Leverage events such as iPHEX 2026 to showcase capabilities and attract overseas buyers.
These steps aim to position India as a trusted global partner for affordable medicines, advanced healthcare technologies, and resilient supply chains.